Compare AbCellera Biologics Inc (ABCL) vs Etsy Inc (ETSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbCellera Biologics Inc vs Etsy Inc — how do they compare? AbCellera Biologics Inc trades at $9.23 (market cap $2.99B), while Etsy Inc trades at $79.71 (market cap $7.29B). The key difference: Etsy Inc is far larger — about 2.4× AbCellera Biologics Inc's market cap. Which is the better fit depends on your goals.
| ABCL | ETSY | |
|---|---|---|
Market Cap | $2.99B | $7.29B |
Sector | Health | Consumer Cyclical |
52-Week High | $9.76 | $86.47 |
52-Week Low | $2.78 | $44.05 |
Enterprise Value | $2.58B | $9.25B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) surged 34.78% to $9.34, driven by positive Phase 2 trial results for its menopause drug ABCL635. Despite negative net income margins and cash burn, analyst consensus is strongly bullish with a $15.50 price target. The stock shows a bullish technical trend, with support at $8 and resistance at $10, though RSI levels indicate overbought conditions.
The outlook hinges on ABCL635's clinical progress and future revenue potential, but high valuation ratios and persistent losses pose significant risks. Investor sentiment is optimistic due to recent drug trial success, yet the company must demonstrate a path to profitability to justify current market enthusiasm.
ETSY trades at $80.40, down 6.02% on the day, with a bearish technical signal despite recent earnings beats. The company reported strong Q2 2026 results with EPS of $0.98 beating expectations of $0.747, while announcing a 12% workforce reduction and $2 billion share repurchase program. Revenue trends show modest growth from $2.6B in 2022 to $2.9B in 2025, though net income margins have compressed from 11.19% in 2023 to 5.65% in 2025.
The outlook remains mixed with analyst consensus at Buy (46.7%) versus Hold (46.7%) and an $85.71 price target offering 6.6% upside. Key risks include high debt levels ($2.29B long-term debt), competitive pressures, and execution of restructuring. Positive catalysts include AI integration progress and operational efficiency improvements driving GMS growth acceleration to 7.5% year-over-year.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →
